Advertisement

Topics

How does our understanding of signaling pathways inform treatment decisions in CLL and FL?

12:50 EDT 26 Jul 2017 | ecancermedicalscience

Prof Paolo Ghia speaks at the 'Defining treatment strategies for CLL & FL in the era of targeted therapies' symposium at EHA 2017 about the mechanisms of action and associated adverse effect profiles for idelalisib, ibrutinib and venetoclax. Click here...

Original Article: How does our understanding of signaling pathways inform treatment decisions in CLL and FL?

NEXT ARTICLE

More From BioPortfolio on "How does our understanding of signaling pathways inform treatment decisions in CLL and FL?"

Advertisement
Quick Search
Advertisement
Advertisement